Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products...
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products...
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementiasWASHINGTON, July 22, 2025 (GLOBE...
– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or...
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Firm targets control investments in essential service and manufacturing businesses with $2–$30 million in revenue and $1–$3 million in EBITDA....
Firm targets control investments in essential service and manufacturing businesses with $2–$30 million in revenue and $1–$3 million in EBITDA....
—Top 4% of Global Applicants Selected to Compete for $800K in Non-Dilutive Funding and Unmatched Industry Access— —Up to 13...
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland -...
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE,...
Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in...
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,...
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July...
In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL StudyPITTSBURGH, July...
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses...
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering...
XIAMEN, China, July 18, 2025 /PRNewswire/ -- Brain-Computer Interface (BCI) technology is redefining human-machine interaction by establishing direct communication between...
Global research award celebrates transformative AI solutions in the fields of neuroscience, biochemistry, and climatology. REDWOOD CITY, Calif., July 17,...
Expanded Executive Team Brings Deep Expertise in Care Delivery, Operations, and Product Development to Support Expansion AUSTIN, Texas, July 17,...
Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and...
CHICAGO, July 17, 2025 (GLOBE NEWSWIRE) -- Neurogen Biomarking will present novel data on at-home p-tau 217 testing for Alzheimer’s...